Utilities were generated from the ipilimumab MDX@-@ trial ( Clinicaltrials.gov Identifier : NCT@ ) using the condition-specific EORTC QLQ-C@ ( via the EORTC-@D ) and generic SF-@v@ ( via the SF-@D ) preference-based measures .